Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Nephrology has benefited from conducting increasingly large high-quality trials in the last 5- 10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain typ...

Fuld beskrivelse

Bibliografiske detaljer
Main Authors:	Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P
Format:	Journal article
Sprog:	English
Udgivet:	Oxford University Press 2025

Lignende værker

Kidney disease trials for the 21st century: innovations in design and conduct
af: Herrington, W, et al.
Udgivet: (2019)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
af: Mayne, K, et al.
Udgivet: (2024)

Renoprotective effect of pentoxifylline in advanced chronic kidney disease
af: Chih-Chin Kao
Udgivet: (2015-01-01)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
af: Preiss, D, et al.
Udgivet: (2022)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
af: Zhu, D, et al.
Udgivet: (2025)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
af: Staplin, N, et al.
Udgivet: (2023)

Chronic kidney disease, heart failure and neprilysin inhibition
af: Haynes, R, et al.
Udgivet: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
af: Zhu, P, et al.
Udgivet: (2020)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
af: Silvie Hojná, et al.
Udgivet: (2022-10-01)

Comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
af: Mahmoud Rafieian-Kopaei
Udgivet: (2014-01-01)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
af: Staplin, N, et al.
Udgivet: (2022)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
af: John S. Clemmer, et al.
Udgivet: (2023-11-01)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
af: Mark R. Hanudel, et al.
Udgivet: (2022-04-01)

Reply to comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
af: Pei-Ying Yeh, et al.
Udgivet: (2014-01-01)

Editorial: Recent advances on renoprotection and kidney regeneration
af: Ignacio Gimenez, et al.
Udgivet: (2023-04-01)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
af: Mayne, KM, et al.
Udgivet: (2024)

Renoprotective effect of febuxostat on contrast-induced acute kidney injury in chronic kidney disease patients stage 3: randomized controlled trial
af: Iman Ibrahim Sarhan, et al.
Udgivet: (2023-03-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
af: Herrington, W, et al.
Udgivet: (2022)

Renoprotective effect of stevia residue extract on adenine-induced chronic kidney disease in mice
af: Arshad Mehmood, et al.
Udgivet: (2020-09-01)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
af: Haynes, R, et al.
Udgivet: (2018)

PERINDOPRIL: THE POSSIBILITY OF ANTIHYPERTENSIVE AND RENOPROTECTIVE THERAPY
af: O. V. Dralova, et al.
Udgivet: (2016-01-01)

Efficacy of Low-Protein Diet and Ketoanalogues of Amino Acids as a Complex of Renoprotective Agents in the Therapy of Chronic Kidney Disease
af: O.O. Dobrik
Udgivet: (2013-08-01)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
af: Mayne, K, et al.
Udgivet: (2023)

Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus
af: S.V. Kushnirenko, et al.
Udgivet: (2021-09-01)

Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study
af: Akinori Yamaguchi, et al.
Udgivet: (2017-05-01)

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease
af: Judge, PK, et al.
Udgivet: (2021)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
af: Judge, PK, et al.
Udgivet: (2024)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
af: Haynes, R, et al.
Udgivet: (2018)

The renoprotective effect of Tibolone in sepsis-induced acute kidney injury
af: Ejder Saylav Bora, et al.
Udgivet: (2024-11-01)

Evaluating the renoprotective effectiveness of sodium-glucose co-transporter 2 inhibitor therapy in patients with chronic kidney disease: A prospective study
af: Karadžić-Ristanović Vidna, et al.
Udgivet: (2024-01-01)

Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
af: Alexander E Berezin, et al.
Udgivet: (2024-02-01)

Inhibition of α2-adrenoceptor is renoprotective in 5/6 nephrectomy-induced chronic kidney injury rats
af: Kohei Hayashi, et al.
Udgivet: (2021-01-01)

The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease
af: Natsumi Tomita, et al.
Udgivet: (2020-09-01)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
af: Herrington, W, et al.
Udgivet: (2016)

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data
af: Haynes, R, et al.
Udgivet: (2016)

THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL
af: V. V. Elagin, et al.
Udgivet: (2018-12-01)

Suppressed renoprotective purines in COVID-19 patients with acute kidney injury
af: Edwin K. Jackson, et al.
Udgivet: (2022-10-01)

Diabetic Kidney Disease in Childhood and Adolescence: Conventional and Novel Renoprotective Strategies
af: Samuel N. Uwaezuoke, et al.
Udgivet: (2020-07-01)

Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?
af: A. Y. Babenko, et al.
Udgivet: (2015-12-01)

Neprilysin inhibition in chronic kidney disease.
af: Judge, P, et al.
Udgivet: (2014)